Detalhe da pesquisa
1.
INOVATYON/ ENGOT-ov5 study: Randomized phase III international study comparing trabectedin/pegylated liposomal doxorubicin (PLD) followed by platinum at progression vs carboplatin/PLD in patients with recurrent ovarian cancer progressing within 6-12 months after last platinum line.
Br J Cancer
; 128(8): 1503-1513, 2023 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-36759720
2.
Surgery due to mechanical bowel obstruction in relapsed ovarian cancer: clinical and surgical results of a bicentric analysis of 87 patients.
Arch Gynecol Obstet
; 305(4): 963-968, 2022 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-34596738
3.
Influence of migrant background on patient preference and expectations in breast and gynecological malignancies (NOGGO-expression V study): results of a prospective multicentre study in 606 patients in Germany.
BMC Cancer
; 21(1): 1018, 2021 Sep 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-34511112
4.
The prognostic and predictive role of pain before systemic chemotherapy in recurrent ovarian cancer: an individual participant data meta-analysis of the North-Eastern German Society of Gynecological Oncology (NOGGO) of 1226 patients.
Support Care Cancer
; 28(4): 1997-2003, 2020 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-31385100
5.
Prognostic role of chemotherapy-induced nausea and vomiting in recurrent ovarian cancer patients: results of an individual participant data meta-analysis in 1213.
Support Care Cancer
; 28(1): 73-78, 2020 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-30980260
6.
Survival and prognostic factors in patients with recurrent low-grade epithelial ovarian cancer: An analysis of five prospective phase II/III trials of NOGGO metadata base.
Gynecol Oncol
; 154(3): 539-546, 2019 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-31230821
7.
Expression III: patients' expectations and preferences regarding physician-patient relationship and clinical management-results of the international NOGGO/ENGOT-ov4-GCIG study in 1830 ovarian cancer patients from European countries.
Ann Oncol
; 29(4): 910-916, 2018 04 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29415128
8.
Prevention of palmoplantar erythrodysesthesia in patients treated with pegylated liposomal doxorubicin (Caelyx®).
Support Care Cancer
; 25(11): 3545-3549, 2017 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-28653108
9.
Correction to: Surgery due to mechanical bowel obstruction in relapsed ovarian cancer: clinical and surgical results of a bicentric analysis of 87 patients.
Arch Gynecol Obstet
; 306(1): 291-292, 2022 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-34807282
10.
Topotecan plus carboplatin versus standard therapy with paclitaxel plus carboplatin (PC) or gemcitabine plus carboplatin (GC) or pegylated liposomal doxorubicin plus carboplatin (PLDC): a randomized phase III trial of the NOGGO-AGO-Study Group-AGO Austria and GEICO-ENGOT-GCIG intergroup study (HECTOR).
Ann Oncol
; 27(12): 2236-2241, 2016 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-27789470
11.
The influence of polypharmacy on grade III/IV toxicity, prior discontinuation of chemotherapy and overall survival in ovarian cancer.
Gynecol Oncol
; 140(3): 554-8, 2016 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-26790772
12.
The influence of comorbidity and comedication on grade III/IV toxicity and prior discontinuation of chemotherapy in recurrent ovarian cancer patients: An individual participant data meta-analysis of the North-Eastern German Society of Gynecological Oncology (NOGGO).
Gynecol Oncol
; 138(3): 735-40, 2015 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-26185017
13.
Intra- and postoperative catumaxomab in patients with epithelial ovarian cancer: safety and two-year efficacy results from a multicentre, single-arm, phase II study.
Br J Cancer
; 111(8): 1519-25, 2014 Oct 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-25225907
14.
Role of serum concentration of VEGFR1 and TIMP2 on clinical outcome in primary cervical cancer: results of a companion protocol of the randomized, NOGGO-AGO phase III adjuvant trial of simultaneous cisplatin-based radiochemotherapy vs. carboplatin and paclitaxel containing sequential radiotherapy.
Cytokine
; 61(3): 755-8, 2013 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-23415672
15.
The time interval from surgery to start of chemotherapy significantly impacts prognosis in patients with advanced serous ovarian carcinoma - analysis of patient data in the prospective OVCAD study.
Gynecol Oncol
; 131(1): 15-20, 2013 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-23877013
16.
Preoperative HE4 expression in plasma predicts surgical outcome in primary ovarian cancer patients: results from the OVCAD study.
Gynecol Oncol
; 128(2): 245-51, 2013 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-23178313
17.
Sequential chemotherapy with carboplatin followed by weekly paclitaxel in advanced ovarian cancer: results of a multicenter phase II study of the northeastern German society of gynecological oncology.
Gynecol Oncol
; 116(3): 317-22, 2010 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-19959213
18.
Clinical management of borderline tumours of the ovary: results of a multicentre survey of 323 clinics in Germany.
Br J Cancer
; 100(11): 1731-8, 2009 Jun 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-19436295
19.
Online tumor conference in the clinical management of gynecological cancer: experience from a pilot study in Germany.
Int J Gynecol Cancer
; 18(1): 1-7, 2008.
Artigo
em Inglês
| MEDLINE | ID: mdl-17466034
20.
PARP Inhibitors for Recurrent Ovarian Carcinoma: Current Treatment Options and Future Perspectives.
Geburtshilfe Frauenheilkd
; 76(2): 164-169, 2016 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-26941449